论文部分内容阅读
目的 揭示胃癌及肠化组织中MUC1基因的表达与其临床病理行为之间的联系。方法 用BC2抗体和免疫组化SP法检测人正常胃肠道粘膜、肠化粘膜以及胃癌组织中MUC1基因核心肽的表达。结果 人正常胃粘膜组织中广泛分布MUC1基因产物 (10 0 % ) ,抗原主要位于上皮层和胃腺的中下部 ;肠化和胃癌组织中的表达阳性率分别为 79 3%和 82 6 % ;胃癌组织中MUC1基因表达与患者的性别、部位、大小、淋巴结转移、分化类型、浸润深度、临床分期和Lauren氏分型之间无关 (P >0 0 5) ;但MUC1基因强阳性者与中弱阳性者之间的临床分期存在明显的差别 (P <0 0 5) ,表达越强 ,Ⅰ～Ⅱ期的可能性越小 ;不同类型肠化中MUC1基因的表达无差异 (P >0 0 5)。结论 上述结果提示用BC2抗体检测的MUC1基因可能是胃癌进展的有用标志 ,可能与胃癌患者的临床病理行为之间有关 ,而与肠化分型无关。
Objective To reveal the relationship between the expression of MUC1 gene and its clinicopathological behavior in gastric cancer and intestinal metaplasia. Methods BC2 antibody and immunohistochemistry SP method were used to detect the expression of MUC1 gene core peptide in human normal gastrointestinal mucosa, intestinal metaplasia and gastric cancer. Results The MUC1 gene product (100%) was widely distributed in normal gastric mucosa, and the antigen was mainly located in the lower part of the epithelium and the gastric gland. The positive rate of intestinal metastasis and gastric cancer was 79 3% and 82 6 % respectively. MUC1 gene expression was not related to patient’s gender, location, size, lymph node metastasis, differentiation type, depth of invasion, clinical stage, and Lauren’s classification (P > 0.05); however, the MUC1 gene was strongly positive and moderately weak. There was a significant difference in the clinical stage between positive patients (P < 0.05). The stronger the expression, the less likely the I-II stage was; the difference in MUC1 gene expression among different types of intestinal metaplasia (P > 0 0 5 ). Conclusion The above results suggest that the MUC1 gene detected by BC2 antibody may be a useful marker for the progression of gastric cancer and may be related to the clinicopathological behavior of gastric cancer patients, but not to the intestinal metaplasia.